About 1,300 children ages 2 to 5 with cystic fibrosis in the U.S. will be eligible to take a drug that Vertex Pharmaceuticals already markets for older patients, as a result of a government ruling.
The Food and Drug Administration on Tuesday approved the expanded use of Orkambi after finding that it was generally safe and well tolerated for 24 weeks, with a safety profile similar to that in patients 6 years old and older.
